"Quinuclidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011812
|
| MeSH Number(s) |
D03.605.687
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinuclidines".
Below are MeSH descriptors whose meaning is more specific than "Quinuclidines".
This graph shows the total number of publications written about "Quinuclidines" by people in this website by year, and whether "Quinuclidines" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Quinuclidines" by people in Profiles.
-
Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
-
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA. Int J Chron Obstruct Pulmon Dis. 2023; 18:407-418.
-
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respir Med. 2022 12; 205:107040.
-
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials. Int J Chron Obstruct Pulmon Dis. 2021; 16:1925-1938.
-
Pharmacologic profiling of patient-derived xenograft models of primary treatment-na?ve triple-negative breast cancer. Sci Rep. 2020 10 21; 10(1):17899.
-
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. Chest. 2021 03; 159(3):985-995.
-
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021 01; 9(1):69-84.
-
Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. J Support Oncol. 2010 Nov-Dec; 8(6):242-51.